IPO
IPO filing, visualized

Tarsier Pharma Ltd.

TARX · NYSEIsraelF-1/A · Jul 16, 2026Filed

No price range yet · latest SEC filing Jul 16, 2026.

Pinch-zoom for details.

The offering

Price range
$8–$10
per share
Shares offered
5.56M
+833K over-allotment option
Raise at $9 midpoint
$50.0M
5,555,555 × $9, before fees

What the company does

Late clinical-stage drug developer for inflammatory eye diseases that can cause blindness.

Things to weigh

  • The filing's financial tables couldn't be read reliably, so none are shown here.

Risks

  1. We are a clinical stage pharmaceutical company and we have incurred significant losses since our inception and anticipate…
  2. We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements
  3. Even if this offering is successful, we expect that we will need to raise substantial additional funding before we can expect to complete the…
  4. We depend substantially on the success of our product candidates and their clinical trials
  5. Our prior phase 3 trial did not meet its primary endpoint (ACC = 0), and future trials may also fail…
  6. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes

The filing's own risk-factor headings, shortened.

Strategy

  1. Completing development and obtaining approval of TRS01 for the treatment of non -infectious anterior uveitis…
  2. Launching focused marketing activities to commercialize TRS01 in the U.S. using a staged commercialization approach
  3. Post launch, broadening the label of TRS01
  4. Launch outside the United States
  5. Developing TRS02 for additional indications associated with uveitis and other back -of - the-eye ocular inflammatory diseases

The filing's own strategy headings, shortened.

Source: Tarsier Pharma Ltd.'s Form F-1/A, filed with the SEC on Jul 16, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.